Loss of P16INK4 expression is frequent in high grade gliomas
R Nishikawa1, F B Furnari, H Lin
1Ludwig Institute for Cancer Research, University of California-San Diego, La Jolla 92093, USA.
Abstract:
P16INK4 is a cell cycle regulator that specifically binds to and inactivates cyclin-dependent kinase 4 (CDK4). Its encoding gene (p16/CDKN2) maps to chromosome 9p21, a region that undergoes frequent loss of heterozygosity in a variety of human tumors. We have analyzed the p16/CDKN2 gene and its expression in a series of primary glioma samples. Although homozygous deletion or mutation of the p16/CDKN2 gene was uncommon in this series and P16INK4 protein was detectable in all grade II tumors, it was present in only 50% of grade III and grade IV samples. Conversely, in some grade IV tumors that level of P16INK4 protein was elevated; in these cases, its target, CDK4, was amplified and overexpressed. These results suggest: (a) the involvement of P16INK4 in glioma progression; (b) that mechanisms other than mutation or deletion can down-regulate expression of the p16/CDKN2 gene; and (c) that the balance between CDK4 and its cognate inhibitor, P16INK4, may confer a cell growth advantage and facilitate tumor progression.
Insights
The P16INK4 protein, a cell cycle regulator, shows decreased presence in high-grade gliomas. Its balance with CDK4 is crucial for glioma progression and tumor growth.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- The P16INK4 protein is a cell cycle regulator that inhibits cyclin-dependent kinase 4 (CDK4).
- The gene encoding P16INK4 (p16/CDKN2) is located on chromosome 9p21, a region frequently altered in human tumors.
- Alterations in cell cycle regulators are implicated in cancer development and progression.
Purpose of the Study:
- To investigate the role of the p16/CDKN2 gene and P16INK4 protein in glioma progression.
- To analyze the expression patterns of P16INK4 and its target CDK4 in primary glioma samples.
- To understand the mechanisms affecting p16/CDKN2 gene expression in gliomas.
Main Methods:
- Analysis of the p16/CDKN2 gene and P16INK4 protein expression in primary glioma samples.
- Assessment of gene deletion, mutation, and protein levels.
- Evaluation of CDK4 amplification and overexpression.
Main Results:
- Homozygous deletion or mutation of p16/CDKN2 was uncommon in the studied gliomas.
- P16INK4 protein was detected in all grade II gliomas but only 50% of grade III and IV gliomas.
- Elevated P16INK4 protein levels in some grade IV gliomas correlated with CDK4 amplification and overexpression.
Conclusions:
- P16INK4 plays a role in glioma progression.
- Mechanisms beyond gene deletion or mutation can down-regulate p16/CDKN2 expression.
- The balance between CDK4 and P16INK4 is critical for glioma cell growth and tumor progression.
Related Concept Videos
02:23Abnormal Proliferation
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...